Suzhou Yabao innovative drug sy-008 clinical research application was officially submitted to the Bureau

Suzhou Asia Pharmaceutical Research and Development Co., Ltd. (abbreviation: Suzhou Ya Bao) announced on 2017 01, 12 of its new mechanism for the innovative application of type 2 diabetes mellitus, the sodium glucose co transporter 1 (SGLT1) inhibitor SY-008, has completed the verification of the research site and raw materials by the Provincial Bureau, and formally submitted to the food and Drug Administration of China (CFDA).
The project is the second project of cooperation between Suzhou Yabao and Eli Lilly. Within two and a half years of its establishment, it has successfully submitted preclinical research data of two class 1 innovative drug projects in China. This was achieved thanks to the excellent team with rich domestic innovative drug development experience built by the founder Dr. Wang Peng, Lilly's original R & D data base, and the joint efforts of all partners.
About sy-008
Sy-008, sodium glucose co transporter SGLT1 molecule
The diet structure of the Chinese population is dominated by carbohydrates. SGLT1 inhibitors can achieve hypoglycemic effect by inhibiting the absorption of glucose in the intestine, and significantly reduce postprandial blood glucose (more than 80% of Chinese patients with postprandial hyperglycemia). It is expected to become a first in class drug worldwide. Acarbose, a domestic first-line drug with similar action mechanism, is an oral hypoglycemic drug with current sales, but the incidence of gastrointestinal adverse reactions is about 25%.

Next:Nothing